Dividendos de Intellia Therapeutics

Dividendo controles de criterios 0/6

Intellia Therapeutics no tiene antecedentes de pago de dividendos.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria	2.9%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	-US$5.01
Rentabilidad por dividendo prevista a 3 años	0%

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

Intellia Therapeutics Is On The Move

Feb 29

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 24

Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier

Feb 09

Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?

Feb 07

Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?

Jan 01

Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans

Oct 20

Intellia Therapeutics: Top Speculative Trade In The Biotech Space

Oct 05

Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling

Sep 01

Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022

Feb 09

Intellia: Best All-Around Gene Editing Company

Jan 27

We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth

Dec 31

Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans

Dec 15

Intellia Stock: Setting Up For Success

Nov 29

Intellia: A Step Closer To A Life-Changing Cure

Nov 21

Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Intrinsic Value Is Potentially 79% Above Its Share Price

Oct 11

Intellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon

Aug 31

Here's Why We're Not At All Concerned With Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Situation

Aug 01

Estimating The Intrinsic Value Of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Jul 05

Intellia Makes History. Can It Deliver A Cure?

Jun 28

Intellia Therapeutics Q1 2021 Earnings Preview

May 05

Intellia Expands Its In Vivo Advantage

May 02

Companies Like Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Invest In Growth

Apr 16

Broker Revenue Forecasts For Intellia Therapeutics, Inc. (NASDAQ:NTLA) Are Surging Higher

Mar 12

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de NTLA han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de NTLA han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Intellia Therapeutics vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de NTLA con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (NTLA)	n/a
Suelo de mercado 25% (US)	1.6%
Techo de mercado 25% (US)	4.9%
Media de la industria (Biotechs)	2.9%
Previsión de analistas en 3 años (NTLA)	0%

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de NTLA en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de NTLA en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de reparto de NTLA para determinar si sus dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que NTLA no ha comunicado ningún pago.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Dividendos de Intellia Therapeutics

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

Intellia Therapeutics Is On The Move

Intellia Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $375.727167 million.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

New major risk - Revenue and earnings growth

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier

Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

President recently sold US$566k worth of stock

Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?

Independent Director notifies of intention to sell stock

Intellia Therapeutics, Inc. Announces Resignation of John F. Crowley from the Board of Directors of Company and Its Committees

Third quarter 2023 earnings: EPS exceeds analyst expectations

Intellia Therapeutics, Inc. Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 At the 4th International ATTR Amyloidosis Meeting

Insufficient new directors

Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Intellia Therapeutics, Inc. Appoints Eliana Clark, Phd, Executive Vice President and Chief Technical Officer

Intellia Therapeutics, Inc. Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Announces Resignation of Jean-François Formela as Board Member

First quarter 2023 earnings released: US$1.18 loss per share (vs US$1.97 loss in 1Q 2022)

Price target decreased by 7.1% to US$96.27

Full year 2022 earnings released: US$6.16 loss per share (vs US$3.78 loss in FY 2021)

Executive VP & Chief Scientific Officer notifies of intention to sell stock

President recently sold US$248k worth of stock

Intellia Therapeutics Presents New Interim Data from First-In-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001

Third quarter 2022 earnings released: US$1.49 loss per share (vs US$0.97 loss in 3Q 2021)

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting

Intellia Therapeutics: Top Speculative Trade In The Biotech Space

Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema

Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling

Intellia Therapeutics, Inc. to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema At the 2022 Bradykinin Symposium

Consensus forecasts updated

Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Intellia Therapeutics down 12% following bottom line Q2 earnings miss

Intellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me Bearish

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announces Additional Positive Interim Data from an Ongoing Phase 1 Study of Their Lead Investigational in Vivo Genome Editing Candidate, NTLA-2001

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022

Intellia Therapeutics: Several Catalysts Expected For H2 2022

Consensus forecasts updated

Price target decreased to US$137

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Intellia Therapeutics, Inc. Names Muna Bhanji to Its Board of Directors

Intellia Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

Price target decreased to US$155

Intellia: One Patent Ruling Turns The Industry Upside Down

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for Treatment of Acute Myeloid Leukemia

Consensus forecasts updated

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Intellia Therapeutics: A Lot Of News Can Bring The Stock Up

Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022

Intellia Therapeutics, Inc. (NasdaqGM : NTLA) acquired Rewrite Therapeutics, Inc. for $200 million.

Intellia: Best All-Around Gene Editing Company

We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth

Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

Intellia Stock: Setting Up For Success

Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy

Intellia: A Step Closer To A Life-Changing Cure

Executive VP & Chief Medical Officer exercised options and sold US$288k worth of stock

Third quarter 2021 earnings released: US$0.97 loss per share (vs US$0.47 loss in 3Q 2020)

Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Intrinsic Value Is Potentially 79% Above Its Share Price

Independent Director exercised options and sold US$1.1m worth of stock

Executive VP & Chief Medical Officer exercised options and sold US$329k worth of stock

Intellia Therapeutics, Inc. announces U.S. Food and Drug Administration accept the investigational new drug (IND) application for NTLA-5001

Intellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon